Literature DB >> 20460153

Rho kinase and hypertension.

Angela Wirth1.   

Abstract

Arterial hypertension is a multifactorial disease that is characterised by increased peripheral vascular resistance often accompanied by smooth muscle cell hypertrophy and proliferation. Rho kinases (ROCKs) are the most extensively studied effectors of the small G-protein RhoA and abnormalities in RhoA/ROCK signalling have been observed in various cardiovascular disease including hypertension. The RhoA/ROCK-pathway is a key player in different smooth muscle cell functions including contractility, proliferation and migration. Furthermore, there is extensive crosstalk between RhoA/ROCK- and NO-signalling. Therefore, not only ROCK inhibitors but also NO-donators or pleiotropic agents like statins exert their beneficial effects on the cardiovascular system at least in part via Rho/Rho-kinase.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20460153     DOI: 10.1016/j.bbadis.2010.05.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  38 in total

Review 1.  Role of rho kinase in the functional and dysfunctional tonic smooth muscles.

Authors:  Márcio A F de Godoy; Satish Rattan
Journal:  Trends Pharmacol Sci       Date:  2011-04-15       Impact factor: 14.819

Review 2.  Angiotensin II and Cardiovascular-Renal Remodelling in Hypertension: Insights from a Human Model Opposite to Hypertension.

Authors:  Verdiana Ravarotto; Elisa Pagnin; Antonio Fragasso; Giuseppe Maiolino; Lorenzo A Calò
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-03-11

Review 3.  Mechanistic approach to the pathophysiology of target organ damage in hypertension from studies in a human model with characteristics opposite to hypertension: Bartter's and Gitelman's syndromes.

Authors:  L A Calò; G Maiolino
Journal:  J Endocrinol Invest       Date:  2015-03-05       Impact factor: 4.256

4.  ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells.

Authors:  Xuefeng Liu; Virginie Ory; Sandra Chapman; Hang Yuan; Chris Albanese; Bhaskar Kallakury; Olga A Timofeeva; Caitlin Nealon; Aleksandra Dakic; Vera Simic; Bassem R Haddad; Johng S Rhim; Anatoly Dritschilo; Anna Riegel; Alison McBride; Richard Schlegel
Journal:  Am J Pathol       Date:  2011-12-18       Impact factor: 4.307

Review 5.  Rho kinase as a therapeutic target in cardiovascular disease.

Authors:  Michelle Surma; Lei Wei; Jianjian Shi
Journal:  Future Cardiol       Date:  2011-09

6.  Rho kinase inhibitor fasudil mitigates high-cholesterol diet-induced hypercholesterolemia and vascular damage.

Authors:  Nibrass Taher Abdali; Awny H Yaseen; Eman Said; Tarek M Ibrahim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-01-18       Impact factor: 3.000

Review 7.  Potential benefits of rho-kinase inhibition in arterial hypertension.

Authors:  Olaf Grisk
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

8.  Central Angiotensin-II Increases Blood Pressure and Sympathetic Outflow via Rho Kinase Activation in Conscious Rabbits.

Authors:  Peter R Pellegrino; Alicia M Schiller; Karla K V Haack; Irving H Zucker
Journal:  Hypertension       Date:  2016-09-26       Impact factor: 10.190

9.  Behavioural effects of basal ganglia rho-kinase inhibition in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.

Authors:  Salim Yalcin Inan; Burak Cem Soner; Ayse Saide Sahin
Journal:  Metab Brain Dis       Date:  2016-03-21       Impact factor: 3.584

10.  DL0805-2, a novel indazole derivative, relaxes angiotensin II-induced contractions of rat aortic rings by inhibiting Rho kinase and calcium fluxes.

Authors:  Tian-Yi Yuan; Yu-Cai Chen; Hui-Fang Zhang; Li Li; Xiao-Zhen Jiao; Ping Xie; Lian-Hua Fang; Guan-Hua Du
Journal:  Acta Pharmacol Sin       Date:  2016-04-04       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.